SMS Pharmaceuticals Ltd
Q1 FY27, unaudited
- Revenue
- ₹206.96 Cr
- Profit after tax
- ₹21.13 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 206.96 | +5.57% | 886.87 |
| Other income | 1.74 | +194.12% | 8.35 |
| Total income | 208.71 | +6.14% | 895.22 |
| Employee benefit expense | 23.30 | +28.15% | 87.92 |
| Finance costs | 5.50 | −5.84% | 23.08 |
| Depreciation & amortisation | 9.99 | +2.44% | 39.92 |
| Total expenses | 180.57 | +4.51% | 778.95 |
| Profit before tax | 28.14 | +17.95% | 116.27 |
| Tax expense | 7.01 | +24.00% | 28.66 |
| Profit after tax | 21.13 | +16.07% | 87.61 |
| Total comprehensive income | 21.06 | +16.26% | 87.64 |
| Earnings per share, basic | ₹2.26 | ₹9.58 |
|---|---|---|
| Earnings per share, diluted | ₹2.26 | ₹9.58 |
Earnings call
Q4 FY26SMS Pharmaceuticals reported 13% revenue growth to INR887 crores and EBITDA margin expansion to 20% for FY26, with PAT rising 47% to INR102 crores including a contribution from associate VKT Pharma. Management attributed the improvement to backward integration in ibuprofen, favorable product mix and operating leverage, while noting the anti-diabetic segment was deprioritized in favor of ARV and anti-inflammatory APIs. For FY27, management guided to 15% revenue growth and further margin improvement from the FY26 level of 20%, citing geopolitical uncertainty affecting logistics and raw material costs.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 38 published by the exchange
21 Aug 2026
Filing06 Aug 2026
01 Aug 2026
Filing01 Aug 2026
Presentation01 Aug 2026
31 Jul 2026
31 Jul 2026
Filing31 Jul 2026
Filing31 Jul 2026
31 Jul 2026
29 Jul 2026
Board meeting25 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 21 Aug 2026.